Holen Sie sich die Stockscreener-App
54.92
0.77%
0.42
Handel nachbörslich:
55.00
0.08
+0.15%
Schlusskurs vom Vortag:
$54.50
Offen:
$54.84
24-Stunden-Volumen:
2.80M
Relative Volume:
0.98
Marktkapitalisierung:
$3.01B
Einnahmen:
$14.34M
Nettoeinkommen (Verlust:
$-199.00M
KGV:
-14.01
EPS:
-3.92
Netto-Cashflow:
$-183.51M
1W Leistung:
+1.12%
1M Leistung:
+216.00%
6M Leistung:
+463.28%
1J Leistung:
+1,104%
1-Tages-Spanne:
$54.50
$57.57
1-Wochen-Bereich:
$53.02
$60.70
52-Wochen-Spanne:
$4.82
$60.70
Uniqure N V Stock (QURE) Company Profile
Firmenname
Uniqure N V
Sektor
Branche
Telefon
1-339-970-7000
Adresse
PAASHEUVELWEG 25A, AMSTERDAM
Vergleichen Sie QURE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
QURE
Uniqure N V
|
54.92 | 3.36B | 14.34M | -199.00M | -183.51M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
403.30 | 104.83B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
600.00 | 63.59B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.35 | 60.43B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
800.00 | 48.45B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
343.87 | 37.91B | 4.56B | -176.77M | 225.30M | -1.7177 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-14 | Hochstufung | Mizuho | Neutral → Outperform |
| 2025-04-01 | Fortgesetzt | Chardan Capital Markets | Buy |
| 2024-12-10 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-02-29 | Herabstufung | Goldman | Buy → Neutral |
| 2023-12-19 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-03-17 | Hochstufung | UBS | Neutral → Buy |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-05-21 | Eingeleitet | UBS | Neutral |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-01 | Hochstufung | Mizuho | Neutral → Buy |
| 2021-01-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-11-11 | Eingeleitet | Berenberg | Buy |
| 2020-11-09 | Eingeleitet | Jefferies | Buy |
| 2020-11-04 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-10-23 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-08-25 | Eingeleitet | Raymond James | Strong Buy |
| 2020-07-31 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2020-06-25 | Herabstufung | Mizuho | Buy → Neutral |
| 2020-06-25 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-06-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2019-12-03 | Eingeleitet | Cowen | Outperform |
| 2019-12-03 | Eingeleitet | Goldman | Buy |
| 2019-11-05 | Eingeleitet | Credit Suisse | Outperform |
| 2019-10-11 | Eingeleitet | Stifel | Buy |
| 2019-09-25 | Eingeleitet | Bernstein | Outperform |
| 2019-09-12 | Eingeleitet | Mizuho | Buy |
| 2019-07-30 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-07-08 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2019-04-12 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-03-29 | Eingeleitet | Robert W. Baird | Outperform |
Alle ansehen
Uniqure N V Aktie (QURE) Neueste Nachrichten
Will uniQure N.V. bounce back from current supportEarnings Beat & Safe Entry Zone Identification - newser.com
Will uniQure N.V. (UQ1) stock beat value stocksJuly 2025 Sentiment & Accurate Buy Signal Notifications - newser.com
uniQure N.V. stock retracement – recovery analysisDay Trade & Weekly Return Optimization Plans - newser.com
Measuring uniQure N.V.’s beta against major indices2025 Growth vs Value & Safe Entry Momentum Stock Tips - newser.com
QURE: Why Analysts See Up to 63% Upside After 250% Single-Day Pop - MarketBeat
Morgan Lewis Advises UniQure in $345 Million Public Equity Offering - Morgan Lewis
Is uniQure N.V. (UQ1) stock nearing a technical breakoutWeekly Investment Report & AI Based Buy and Sell Signals - newser.com
Visual trend scoring systems applied to uniQure N.V.Quarterly Performance Summary & High Accuracy Swing Entry Alerts - newser.com
How to build a custom watchlist for uniQure N.V.Portfolio Profit Report & Growth Oriented Trade Recommendations - newser.com
Is uniQure N.V. stock a safe investment in uncertain marketsMarket Performance Summary & Risk Controlled Swing Alerts - newser.com
Is uniQure N.V. (UQ1) stock a top dividend aristocrat candidate2025 Institutional Moves & Real-Time Volume Analysis - newser.com
Is uniQure N.V. showing signs of accumulationCEO Change & Short-Term High Return Ideas - newser.com
Is uniQure N.V. meeting your algorithmic filter criteriaJuly 2025 Recap & AI Powered Market Trend Analysis - newser.com
uniQure Completes $345 Million Public Offering of Ordinary Shares and Pre-Funded Warrants - Global Legal Chronicle
Wells Fargo Maintains uniQure N.V. (QURE) Overweight Recommendation - Nasdaq
Wells Fargo Upgrades UniQure NV(QURE.US) to Buy Rating, Raises Target Price to $80 - 富途牛牛
uniQure (QURE) Sees Raised Price Target and Maintained Overweigh - GuruFocus
uniQure Stock Price Target Raised on Blockbuster Opportunity - AskTraders.com
Wells Fargo Maintains UniQure NV(QURE.US) With Buy Rating, Raises Target Price to $80 - 富途牛牛
United States Viral Vector Manufacturing Market Set for Strong - openPR.com
uniQure N.V. (QURE) Price Target Increased by 88.86% to 69.17 - Nasdaq
uniQure NV Hits New 52-Week High of $55.11, Surging 909.48% - Markets Mojo
uniQure N.V. (QURE) Reports Positive Phase I/II Results, Prepares FDA BLA Submission - Insider Monkey
uniQure announces pricing of upsized $300M public offering - MSN
uniQure (NASDAQ:QURE) Reaches New 52-Week HighStill a Buy? - MarketBeat
Is uniQure N.V. stock in correction or buying zoneWeekly Trade Analysis & Technical Buy Zone Confirmations - newser.com
uniQurex (QURE) Nearly Quadruples on Stellar Results for Huntington Disease Treatment - Insider Monkey
uniQure (NASDAQ:QURE) Sees Unusually-High Trading VolumeHere's What Happened - MarketBeat
uniQure completes $345 million public offering to fund gene therapy pipeline - Investing.com India
UniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares - MarketScreener
Silicon Valley - FinancialContent
What drives uniQure NV stock priceStock Price Targets & Minimize Portfolio Damage with Warnings - earlytimes.in
Research Analysts Set Expectations for uniQure Q3 Earnings - MarketBeat
uniQure FY2025 EPS Forecast Reduced by Cantor Fitzgerald - MarketBeat
StockWatch: uniQure Shares Reach Five-Year High on “Game Changing” Huntington’s Data - Genetic Engineering and Biotechnology News
uniQure (QURE) Is Up 291.6% After AMT-130’s Breakthrough Phase I/II Huntington’s Results and FDA Designations – Has The Bull Case Changed? - simplywall.st
uniQure announces $200 million proposed public offering - MSN
Why uniQure (QURE) Is Up After Positive AMT-130 Trial Results and Major New Funding Announcements - Yahoo Finance
Benzinga Bulls And Bears: Oracle, Costco, NIO — And Wall Street Snaps Its Slide - Benzinga
uniQure (QURE) Stock Soars on Huntington’s Breakthrough – Key Facts & 2025 Outlook - ts2.tech
uniQure N.V.: CFO Klemt sells $945k in shares By Investing.com - Investing.com Canada
Finanzdaten der Uniqure N V-Aktie (QURE)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.68%
0.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):